Skip to main content
Figure 7 | Journal of Translational Medicine

Figure 7

From: Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life

Figure 7

Percent change in Gd-DTPA area under the time-concentration curve (AUC) of RG-2 glioma tumor tissue and temporalis skeletal muscle tissue as a result of the 15 minute intravenous infusion of normal saline or respective bradykinin B2 agonist. (A) Anterior brain RG-2 gliomas; NS (N = 6), BK (N = 8), Lys-BK (N = 8), Met-Lys-BK (N = 7), Labradimil (N = 13); (B) Posterior brain RG-2 gliomas; NS (N = 6), BK (N = 8), Lys-BK (N = 8), Met-Lys-BK (N = 7), Labradimil (N = 12); (C) Temporalis skeletal muscle, NS (N = 6), BK (N = 8), Lys-BK (N = 8), Met-Lys-BK (N = 7), Labradimil (N = 13). P-values reported are adjusted values using Dunnett-Hsu adjustments for multiple post hoc comparisons of treatment effect.

Back to article page